Viridian Therapeutics, Inc.
VRDN
$12.38
-$0.43-3.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -41.35% | -13.55% | -18.66% | -15.24% | -26.57% |
| Total Depreciation and Amortization | -11.01% | -6.20% | 46.72% | 1,344.21% | 519.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -53.61% | -56.55% | 1.24% | 38.21% | 110.68% |
| Change in Net Operating Assets | 108.63% | 201.84% | 289.54% | 1,085.04% | -180.65% |
| Cash from Operations | -67.09% | -26.14% | -9.31% | -3.93% | -24.23% |
| Capital Expenditure | 23.75% | 43.10% | 58.83% | 27.98% | -6.82% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 106.74% | -144.38% | -221.92% | -84.20% | -63.47% |
| Cash from Investing | 106.45% | -142.60% | -219.04% | -83.42% | -63.17% |
| Total Debt Issued | -- | -- | -100.00% | 3,263.23% | 200.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -13.62% | 213.15% | 1,322.54% | 5.52% | 7.53% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -67.19% | -67.19% | -- | 73.16% | 73.16% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 26.09% | -118.77% | -1,884.78% | -1.26% | -0.81% |
| Cash from Financing | -26.53% | 102.83% | 1,077.70% | 19.31% | 19.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 686.12% | 93.87% | 138.14% | -63.10% | -94.58% |